Literature DB >> 28175963

Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer.

Jing Zhang1, Jinyu Liu2, Xinyan Xu1, Li Li3.   

Abstract

PURPOSE: To investigate how curcumin alters the extracellular vesicles' (EVs) capability to ship drug resistance in ovarian cancer.
METHODS: The EVs from cisplatin-resistant A2780cp cells with curcumin treatment (EVs-CU) or without curcumin treatment (EVs-N) were collected for lncRNA profiling. Curcumin's effect on MEG3 promoter methylation and MEG3 expression were studied by MSP and qRT-PCR, respectively. The regulative effect of MEG3 on miR-214 expression and the functional role of EVs mediated transfer of miR-214 in cisplatin resistance were further investigated.
RESULTS: Curcumin weakened the EVs-N's capability to induce drug resistance and induced significant changes of lncRNAs in the EVs. MEG3 is one of the most upregulated lncRNAs. Curcumin led to demethylation in the promoter region of MEG3 and 5-AZA-dC treatment restored MEG3 expression in a dose dependent manner. There were at least two binding sites between MEG3 and miR-214. MEG3 restoration by curcumin significantly reduced miR-214 in cells and in EVs. Functionally, miR-214 inhibition weakened the EVs-N's capability to enhance chemoresistance, while miR-214 overexpression increased the capability of EVs-CU in inducing chemoresistance.
CONCLUSION: Curcumin can restore MEG3 levels via demethylation. MEG3 upregulation can decrease EVs mediated transfer of miR-214 in ovarian cancer cells, thereby reducing drug resistance.

Entities:  

Keywords:  Cisplatin resistance; Curcumin; Extracellular vesicles; MEG3; MiR-214; Ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 28175963     DOI: 10.1007/s00280-017-3238-4

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  34 in total

1.  LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN.

Authors:  Juelan Wang; Wenqian Xu; Yangke He; Qi Xia; Siwei Liu
Journal:  Inflamm Res       Date:  2018-10-11       Impact factor: 4.575

Review 2.  MEG3: an Oncogenic Long Non-coding RNA in Different Cancers.

Authors:  Arwa Al-Rugeebah; Mohammed Alanazi; Narasimha Reddy Parine
Journal:  Pathol Oncol Res       Date:  2019-02-21       Impact factor: 3.201

Review 3.  Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases.

Authors:  Shruti Mishra; Sumit S Verma; Vipin Rai; Nikee Awasthee; Srinivas Chava; Kam Man Hui; Alan Prem Kumar; Kishore B Challagundla; Gautam Sethi; Subash C Gupta
Journal:  Cell Mol Life Sci       Date:  2019-03-16       Impact factor: 9.261

4.  Role of Curcumin in Regulating Long Noncoding RNA Expression in Cancer.

Authors:  Abolfazl Amini; Parand Khadivar; Ali Ahmadnia; Morteza Alipour; Muhammed Majeed; Tannaz Jamialahmadi; Thozhukat Sathyapalan; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells.

Authors:  Priya Samuel; Laura Ann Mulcahy; Fiona Furlong; Helen O McCarthy; Susan Ann Brooks; Muller Fabbri; Ryan Charles Pink; David Raul Francisco Carter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

Review 6.  Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes.

Authors:  Manish K Tripathi; Kyle Doxtater; Fatemeh Keramatnia; Chidi Zacheaus; Murali M Yallapu; Meena Jaggi; Subhash C Chauhan
Journal:  Drug Discov Today       Date:  2018-04-23       Impact factor: 7.851

7.  DSCMF: prediction of LncRNA-disease associations based on dual sparse collaborative matrix factorization.

Authors:  Jin-Xing Liu; Ming-Ming Gao; Zhen Cui; Ying-Lian Gao; Feng Li
Journal:  BMC Bioinformatics       Date:  2021-05-12       Impact factor: 3.169

8.  Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles.

Authors:  Muhammad Muzamil Khan; Asadullah Madni; Nayab Tahir; Farzana Parveen; Safiullah Khan; Nasrullah Jan; Ahsan Ali; Muhammad Abdurrahim; Umar Farooq; Muhammad Imran Khan
Journal:  Int J Nanomedicine       Date:  2020-03-30

9.  The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer.

Authors:  Monal Patel; Yinu Wang; Elizabeth T Bartom; Rohin Dhir; Kenneth P Nephew; Daniela Matei; Andrea E Murmann; Ernst Lengyel; Marcus E Peter
Journal:  Cancer Res       Date:  2021-06-15       Impact factor: 12.701

10.  Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling.

Authors:  L Gao; T Shao; W Zheng; J Ding
Journal:  Clin Transl Oncol       Date:  2021-02-10       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.